That's a great question. Adagrasib (Krazati) is a targeted therapy approved for non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. It can be considered as a second- or third-line treatment option after progression on other therapies, including immunotherapy.
When cancer progresses after first-line treatment Show Full Answer
That's a great question. Adagrasib (Krazati) is a targeted therapy approved for non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. It can be considered as a second- or third-line treatment option after progression on other therapies, including immunotherapy.
When cancer progresses after first-line treatment, doctors look at several factors to decide next steps:
- Where the cancer has spread
- Tumor size
- Your overall treatment goals
- Your specific genetic mutations (like KRAS G12C)
If you have the KRAS G12C mutation, adagrasib may be a viable option after immunotherapy progression. It's worth having a detailed conversation with your oncologist about whether this fits your situation. It's also worth asking your oncologist about clinical trials, as they may give access to newer or combination treatments that could be beneficial after progression.
Every lung cancer journey is different, so getting personalized guidance from your care team is really important here.
April 23
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
